What are the side effects and drug interactions of XYWAV (calcium, magnesium, potassium, and sodium oxybates)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 13, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

XYWAV: Side Effects and Drug Interactions

XYWAV (calcium, magnesium, potassium, and sodium oxybates) carries an FDA black box warning as a CNS depressant that can cause respiratory depression, and it is a Schedule III controlled substance with significant abuse potential—particularly dangerous when combined with alcohol or other CNS depressants. 1

Critical Safety Warnings

Black Box Warning: CNS Depression and Abuse Potential

  • XYWAV is the mixed-salt formulation of gamma-hydroxybutyrate (GHB), a Schedule I controlled substance 1
  • Abuse or misuse is associated with seizures, respiratory depression, decreased consciousness, coma, and death—especially when combined with other CNS depressants like alcohol or sedating medications 2
  • Available only through a Risk Evaluation and Mitigation Strategy (REMS) program using certified pharmacies 2, 1

Respiratory Depression

  • Can cause slower breathing, trouble breathing, and sleep apnea 1
  • Patients with pre-existing breathing or lung problems have higher risk of respiratory complications 1
  • One case report documented respiratory failure requiring mechanical ventilation from mistimed dosing 3

Common Side Effects

Most Frequent Adverse Reactions in Adults (≥5%)

Based on clinical trials in narcolepsy and idiopathic hypersomnia 1:

  • Nausea (13-20%)
  • Headache (20%)
  • Dizziness (10%)
  • Decreased appetite (8%)
  • Anxiety (5%)
  • Insomnia
  • Hyperhidrosis (excessive sweating) (6%)
  • Vomiting (5%)
  • Diarrhea (6%)
  • Dry mouth (4%)
  • Parasomnia (6%)
  • Somnolence
  • Fatigue (4%)
  • Tremor (3%)

Pediatric-Specific Side Effects

In pediatric patients with narcolepsy, the most common adverse reactions (≥5%) included 2, 1:

  • Nausea (20%)
  • Enuresis (bedwetting) (19%)
  • Vomiting (18%)
  • Headache (17%)
  • Weight decreased (13%)
  • Decreased appetite (9%)
  • Dizziness (8%)
  • Sleepwalking (6%)

Serious Psychiatric and Behavioral Reactions

Depression and Suicidality

  • Monitor patients for emergent or increased depression and suicidal ideation 1
  • Rare but serious adverse effects in pediatric trials included depression and suicidality 2

Other Psychiatric Symptoms

  • Confusion, hallucinations, abnormal thinking 1
  • Anxiety, agitation, panic attacks 1
  • Neuropsychiatric reactions including acute psychosis reported in pediatric trials 1

Parasomnias

  • Sleepwalking can occur and may lead to injuries requiring hospitalization 1
  • Five instances of sleepwalking with potential or significant injury reported in clinical trials 1
  • Episodes should be fully evaluated with appropriate interventions 1

Critical Drug Interactions

Absolute Contraindications

XYWAV is contraindicated in combination with: 1

  • Sedative hypnotics
  • Alcohol
  • Patients with succinic semialdehyde dehydrogenase deficiency

Significant Interaction: Divalproex Sodium

  • Concomitant use with divalproex sodium requires at least 20% reduction in XYWAV dose 1
  • This is the only specific drug interaction with dosing guidance provided in the FDA label

General CNS Depressant Interactions

  • Use extreme caution with any other CNS depressants 1
  • The combination significantly increases risk of respiratory depression, decreased consciousness, coma, and death 2

Special Populations and Precautions

Pregnancy and Lactation

  • Based on animal data, may cause fetal harm 2, 1
  • Human data are insufficient to determine risk 2
  • Balance of risks and harms is likely different for pregnant and breastfeeding women 2

Hepatic Impairment

  • Recommended starting dosage is one-half of the original dosage per night, divided into two doses 1

Timing and Administration Risks

  • Patients can fall asleep within 5 minutes, most within 15 minutes 1
  • Falling asleep quickly, including while standing or getting up from bed, has led to falls requiring hospitalization 1
  • Must be taken at least 2 hours after eating 1
  • Mistimed administration can lead to severe consequences including respiratory failure 3

Discontinuation Rates

  • In clinical trials, 4% of patients discontinued due to adverse reactions 1
  • Most common reason for discontinuation was nausea (1.5%) 1
  • Majority of adverse reactions leading to discontinuation began during the first few weeks of treatment 1

Important Clinical Considerations

Cardiovascular Context

  • XYWAV contains 92% less sodium than sodium oxybate, which is clinically meaningful given that patients with narcolepsy have increased cardiovascular risk 4, 5
  • The reduced sodium content is FDA-recognized as reducing cardiovascular morbidity compared to high-sodium oxybates 5

Weight Effects

  • Weight loss observed in clinical trials for both narcolepsy and idiopathic hypersomnia 6
  • Only occasionally led to patients becoming underweight 6

References

2
Guideline

treatment of central disorders of hypersomnolence: an american academy of sleep medicine clinical practice guideline.

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2021

Related Questions

What are the interaction risks of combining Vraylar (cariprazine) with Xywav (calcium, magnesium, potassium, and sodium oxybates)?
How to explain Xywav (calcium, magnesium, potassium, and sodium oxybates) to a patient with a history of narcolepsy?
In a patient with idiopathic hypersomnia taking Xywav (sodium oxybate) 3.75 g nightly split dose (first dose 9:30–10 pm, second dose 1 am) who reports a drugged feeling, reduced efficacy, morning sleepiness, and anxiety about dependence, how should the medication be tapered and what adjunctive measures should be used to manage symptoms?
What monitoring should be performed when initiating therapy with Xyrem (sodium oxybate) and Xywav (low‑sodium oxybate)?
How should I titrate up a patient who is taking 2.25 g of Xywav (calcium, magnesium, potassium, and sodium oxybates) twice nightly?
When should a technetium‑99m DTPA renal scan be ordered and what is the proper protocol for performing it?
What is the recommended management of pneumohydrothorax?
What is the recommended management for acute cryptitis of the colonic mucosa in an adult patient?
What is the diagnosis of choledocholithiasis, its typical presenting complaint, clinical presentation and examination findings, and what is the gold‑standard imaging test (including the role of a full blood count)?
What are the alternatives to blood transfusion for managing anemia or acute blood loss?
Which baseline laboratory tests should be obtained before initiating risperidone therapy?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.